IMS 2022 | An update on the RADAR trial: RCyBorD as induction therapy in newly diagnosed multiple myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, gives an update on the RADAR trial (ISRCTN46841867; UK-MRA Myeloma XV) evaluating the combination of lenalidomide, cyclophosphamide, bortezomib, and dexamethasone (RCyBorD) as induction therapy in patients with newly diagnosed multiple myeloma. Based on the results of the MUK Nine b study (NCT03188172), the trial recently added isatuximab to this treatment regimen in high-risk patients. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
